1. Medtech Insight

Advances in CRM Technology

At this year's Heart Rhythm Society meeting, companies showcased a number of technologies designed to make cardiac rhythm management (CRM) devices, such as implantable cardioverter defibrillators and pacemakers, safer, more effective, and easier to implant. In addition, there were some early-stage presentations on promising next-generation CRM technologies involving leadless and rechargeable systems-paradigm changing advances.

At this year’s Heart Rhythm Society (HRS) meeting, held in May in Boston, MA, companies showcased a number of technologies designed to make cardiac rhythm management (CRM) devices, such as implantable cardioverter defibrillators (ICDs) and pacemakers, safer, more effective, and easier to implant. In addition, there were some very interesting early-stage presentations on promising next-generation CRM technologies involving leadless and rechargeable systems—paradigm-changing advances that will be watched closely as development work continues.

All of the major CRM manufacturers now offer algorithms in their dual-chamber pacemakers and ICDs that are designed to reduce right ventricular pacing (RVP), since several studies have demonstrated that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

SAGA Diagnostics Launches Early Breast Cancer MRD Detection Test In US

 
• By Natasha Barrow

SAGA Diagnostics has launched its breast cancer residual and recurrence detection test – Pathlight – in the US. The test’s ultrahigh sensitivity and specificity is rare to see in oncology, the company claimed.

Siemens Healthineers Widens FY25 EPS Range By €0.15 To Absorb Up To €300M In Tariff Costs

 
• By Shubham Singh

The imaging, Varian, and advanced therapies segments – which are more reliant on equipment sales – are more heavily affected, with tariffs applying to roughly 55% of their revenue base. In diagnostics, the company expects minimal exposure due to sufficient US value-added manufacturing.

FDA Rebukes Four Companies, Including One Overseas, For Procedural Failures

 
• By Brian Bossetta

The US FDA’s device center sent warning letters to three domestic device manufacturers and one German firm for failing to adhere to protocol on several issues.